FlandersBio offers an up-to-date life sciences database with detailed information about all FlandersBio members.
FlandersBio beschikt over een geüpdate life sciences databank met een gedetailleerd overzicht van alle FlandersBio-ledenbedrijven.
Gimv Life Sciences supports promising companies in the life sciences sector with venture capital. Gimv's long-term approach is particularly valuable in this capital-intensive sector characterised by long and unpredictable periods between initial investment and exit. To maximize return on investment and create short- and long-term value for the companies we invest in, Gimv Life Sciences is committed to active involvement at the Board of Directors level.
Representing more than 25 years of investment experience, Gimv is Belgium's most important private equity and venture capital provider and a major European and international market player. The company is listed on Euronext Brussels (share code GIMB). Gimv currently manages a portfolio representing around EUR 2.0 billion of assets (including third party funds). Since its incorporation, Gimv has achieved an average annual return of over 13 percent.
Gimv's ambition is to create added value by investing in promising small to medium-sized companies and to actively accompany and support these companies as a professional and experienced partner in their growth, expansion, operational improvement and financial aptimization. Gimv can take shareholdings in compwnies with enterprise values of up to around € 125 million. It provides capital for growth financing and management buy-outs (MBOs) of private companies in traditional sectors through local offices in Belgium, the Netherlands, France and Germany. Gimv also provides venture capital to companies active in information and communication technology, life sciences and clean tech, both in Belgium and abroad.
The Life Sciences division supports innovative biotech companies with a srong management team to develop first-in-class or best-in-class products for growth markets. They can be active in various areas such as therapeutics, diagnostics, medical devices, agbiotech or white biotech. The aim is to build a diversified portfolio, which not only spreads the risk, but also allows more stable returns in this volatile market. European investment proposals have a higher priority, but we also consider attractive US opportunities. Although our focus is on early stage companies, there is an opportunistic approach whereby investments in later stage companies and public companies (e.g. PIPEs) are not ruled out, as long as the return, the valuation and near-term exit remain attractive.
GIMV Life Sciences invests in innovative biotech companies, which develop new products with high added value for growth markets.
Gimv Life Sciences has invested in the following companies: 7TM Pharma, Ablynx, Acertys, Actogenix, Ambit Biosciences, Antisoma, Astex Technology, Ceres, ChemoCentryx, Diatos, Evotec, Fovea Pharmaceuticals, Galapagos, Innate Pharma, Memory Pharmaceuticals, Movetis, Nereus Pharmaceuticals, Pamgene, Plexxikon, Pronota, Santhera Pharmaceuticals, Thrombogenics.